Please login to the form below

Not currently logged in
Email:
Password:

omecamtiv

This page shows the latest omecamtiv news and features for those working in and with pharma, biotech and healthcare.

Amgen, Cytokinetics’ heart failure drug disappoints in phase 3

Amgen, Cytokinetics’ heart failure drug disappoints in phase 3

The results from the GALACTIC-HF study show that treatment with the drug, omecamtiv mecarbil, hit the primary endpoint of statistical significance on a measure of reduction in hospitalisation or other ... Omecamtiv mecarbil, originally developed by

Latest news

More from news
Approximately 3 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Sale of Priority Review Voucher (PRV). 125. Cytokinetics/ Royalty Pharma. 4.5% royalty on global sales of omecamtiv mecarbil for heart failure (phase III).

  • Heart failure therapy embarks on a new era Heart failure therapy embarks on a new era

    In collaboration with Cytokinetics, Amgen is developing omecamtiv mecarbil, an activator of cardiac myosin that is designed to increase the duration of cardiac muscle contractility and improve cardiac muscle performance.

  • Deal Watch table for July 2013 Deal Watch table for July 2013

    100. ‡‡Servier / Amgen .  Cardiovascular collaboration, licence and option. Procoralan (ivabradine, approved), S38844 (p2), omecamtiv mecarbil (p2). ... rights in Europe for omecamtiv mecarbil. †

  • Pharma deals during July 2013 Pharma deals during July 2013

    the US, and Servier receives an option to omecamtiv mecarbil for Europe. ... Omecamtiv mecarbil is currently in phase II trials for acute and chronic heart failure and is the most advanced drug candidate coming out of Amgen's collaboration with

  • Deal Watch table for June 2013 Deal Watch table for June 2013

    129. Cytokinetics / Amgen. Extension of existing licence to Japan. Small molecules to activate heart muscle, including omecamtiv mecarbil (phase II).

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, healthcare communication services to the pharmaceutical industry across the globe, with a focus...

Latest intelligence

Personalised medicine AI
How early-stage clinical research is facilitating the new wave of personalised medicines
By Jorg Taubel...
patient diversity buckland
Patient diversity in clinical trials needs to be centre stage
By Danny Buckland...
Why empathy in digital patient recruitment is vital
This is where empathy mapping can be incredibly effective....